KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS

Abdallah, Chadi G., Adams, Thomas G., Kelmendi, Benjamin, Esterlis, Irina, Sanacora, Gerard, Krystal, John H.·2016·Depression and Anxiety
DOI 10.1002/da.22501

Cited by (207)

Items 101–200 of 207

  1. The Effect of Glutamatergic Modulators on Extracellular Glutamate: How Does this Information Contribute to the Discovery of Novel Antidepressants?
    Marcos Emílio Frizzo · 2019 · Current Therapeutic Research
  2. Esketamine alleviates LPS-induced depression-like behavior by activating Nrf2-mediated anti-inflammatory response in adolescent mice
    Xinxu Ma, Shanshan Xue, Hongzhe Ma, Saboor Saeed, Yunyun Zhang, Yumeng Meng, Hạixia Chen, Huan Yu, Huaizhi Wang, Shaohua Hu et al. · 2025 · Neuroscience
  3. Trends in Pediatric Pain
    Charlotte M. Walter, Niekoo Abbasian, Vanessa A. Olbrecht · 2020 · Anesthesiology Clinics
  4. Prophylactic efficacy of ketamine, but not the low-trapping NMDA receptor antagonist AZD6765, against stress-induced maladaptive behavior and 4E-BP1-related synaptic protein synthesis impairment
    Anderson Camargo, Ana Clara N. C. Torrá, Ana Paula Dalmagro, Ana Paula Valverde, Bruna R. Kouba, Daiane B. Fraga, Eloise C. Alves, Ana Lúcia S. Rodrigues · 2022 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  5. Molecular Signaling Mechanisms for the Antidepressant Effects of NLX-101, a Selective Cortical 5-HT1A Receptor Biased Agonist
    Sharon Cabanu, Fuencisla Pilar-Cuéllar, Paula Zubakina, Eva Florensa-Zanuy, Júlia Senserrich, Adrian Newman‐Tancredi, Albert Adell · 2022 · Pharmaceuticals
  6. Acute administration of the NMDA receptor antagonists ketamine and MK-801 reveals dysregulation of glutamatergic signalling and sensorimotor gating in the Sapap3 knockout mouse model of compulsive-like behaviour
    James J Gattuso, Carey Wilson, Anthony John Hannan, Thibault Renoir · 2023 · Neuropharmacology
  7. Ketamine induces opposite changes in AMPA receptor calcium permeability in the ventral tegmental area and nucleus accumbens
    Olga Skiteva, Ning Yao, Karima Chergui · 2021 · Translational Psychiatry
  8. Acute effects of ketamine on the pregenual anterior cingulate: linking spontaneous activation, functional connectivity, and glutamate metabolism
    Matti Gärtner, Anne Weigand, Milan Scheidegger, Mick Lehmann, Patrik Oliver Wyss, Andreas Wunder, A Henning, Simone Grimm · 2022 · European Archives of Psychiatry and Clinical Neuroscience
  9. Psilocybin-assisted psychotherapy for dying cancer patients – aiding the final trip
    David Spiegel · 2016 · Journal of Psychopharmacology
  10. Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression
    R. Yan, Tyler Marshall, A. Khullar, T. Nagle, J. Knowles, M. Malkin, Brittany Chubbs, J. Swainson · 2024 · Therapeutic Advances in Psychopharmacology
  11. Efficacy of Esketamine among patients with treatment resistant depression in a ‘real world' health-care setting in Israel
    Lior Dvorak, Esther Bloemhof‐Bris, Assaf Shelef, Dania Halperin, Gay Wexler, Ortal Talmon, Kfir Feffer · 2024 · Journal of Psychiatric Research
  12. Ketamine reverses chronic corticosterone-induced behavioral deficits and hippocampal synaptic dysfunction by regulating eIF4E/BDNF signaling
    Canyu Yang, Tahir Ali, Axiang Li, Ruyan Gao, Xiaoming Yu, Shupeng Li, Tao Li · 2024 · Neuropharmacology
  13. REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats
    Francesco Bifari, Marco Pappagallo, Michael R. Bleavins, Sergio Traversa, Franco B. Folli, Paolo L. Manfredi · 2022 · Frontiers in Pharmacology
  14. Neuroimaging as a Tool for Individualized Treatment Choice in Depression: the Past, the Present and the Future
    Beata R. Godlewska · 2020 · Current Behavioral Neuroscience Reports
  15. S-ketamine ameliorates post-stroke depression in mice via attenuation of neuroinflammation, synaptic restoration, and BDNF pathway activation
    Tian, Jiaxin, Xie, Yanhong, Ye, Sen, Hu, Yongfeng, Feng, Jiaxin, Li, Yi, Lou, Zhongze, Ruan, Liemin, Wang, Zhengchun · 2025 · Biochemical and Biophysical Research Communications
  16. Repeated cannabidiol treatment affects neuroplasticity and endocannabinoid signaling in the prefrontal cortex of the Flinders Sensitive Line (FSL) rat model of depression.
    Luana Barreto Domingos, Heidi Kaastrup Müller, Nicole Rodrigues da Silva, Michaela D. Filiou, Anders Lade Nielsen, Francisco Silveira Guimarães, Gregers Wegener, Sâmia R.L. Joca · 2024 · Neuropharmacology
  17. Spike firing attenuation of serotonin neurons in learned helplessness rats is reversed by ketamine
    Kouichi Hashimoto, Yosuke Yamawaki, Kenji Yamaoka, Takayuki Yoshida, Kana Okada, Wanqin Tan, Miwako Yamasaki, Yoshiko Makidono, Reika Kubo, Hisako Nakayama et al. · 2021 · Brain Communications
  18. Combined Treatment with Low-Dose Ionizing Radiation and Ketamine Induces Adverse Changes in CA1 Neuronal Structure in Male Murine Hippocampi
    Daniela Hladik, Sonja Buratovic, Christine von Toerne, Omid Azimzadeh, Prabal Subedi, Jos Philipp, Stefanie Winkler, Annette Feuchtinger, Elenore Samson, Stefanie M. Hauck et al. · 2019 · International Journal of Molecular Sciences
  19. Kétamine, psilocybine, et antidépresseurs d'action rapide : de nouvelles promesses pour la psychiatrie?
    Hugo Bottemanne, Anne Claret, Philippe Fossati · 2020 · L Encéphale
  20. Does route of administration affect antidepressant efficacy of ketamine? A meta-analysis of double-blind randomized controlled trials comparing intravenous and intranasal administration
    Marvin Sören Meiering, David Weigner, Matti Gärtner, Thomas Schäfer, Simone Grimm · 2022 · Journal of Psychiatric Research
  21. NMDA Antagonists and Their Role in the Management of Bipolar Disorder: a Review
    Rodrigo Simonini Delfino, Juliana Canada Surjan, Igor Dórea Bandeira, Lucas Braziliano, Fernanda S. Correia‐Melo, José Alberto Del-Porto, Lucas C. Quarantini, Acioly L.T. Lacerda · 2020 · Current Behavioral Neuroscience Reports
  22. Guanosine as a promising target for fast-acting antidepressant responses
    Anderson Camargo, Ana Lúcia S. Rodrigues · 2022 · Pharmacology Biochemistry and Behavior
  23. The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
    2023 · International Review of Neurobiology
  24. Effects of stress on endophenotypes of suicide across species: A role for ketamine in risk mitigation
    Steven J. Lamontagne, Elizabeth D. Ballard, Carlos A. Zarate · 2022 · Neurobiology of Stress
  25. A single subanaesthetic dose of the rapid-acting antidepressant S-ketamine raises presynaptic SV2A density in limbic regions of the Wistar Kyoto rat model of depression
    Bærentzen, Simone Larsen, Waszkiewicz, Anna Lee, Thomsen, Majken, Knudsen, Celine, Elfving, Betina, Landau, Anne M. · 2024 · Neuroscience Applied
  26. Guanosine boosts the fast, but not sustained, antidepressant-like and pro-synaptogenic effects of ketamine by stimulating mTORC1-driven signaling pathway
    Anderson Camargo, Ana Paula Dalmagro, Eslen Delanogare, Daiane B. Fraga, Ingrid A.V. Wolin, Ana Lúcia Bertarello Zeni, Patrícia S. Brocardo, Ana Lúcia S. Rodrigues · 2022 · European Neuropsychopharmacology
  27. Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial
    Verònica Gálvez, Stevan Nikolin, Kerrie-Anne Ho, Angelo Alonzo, Andrew Alexander Somogyi, Colleen K A Loo · 2016 · Comprehensive Psychiatry
  28. Functional activity and connectivity signatures of ketamine and lamotrigine during negative emotional processing: a double-blind randomized controlled fMRI study
    Marvin Sören Meiering, David Weigner, Matti Gärtner, Luisa Carstens, Christian Keicher, Rita Hertrampf, Christian F. Beckmann, Maarten Mennes, Andreas Wunder, Anne Weigand et al. · 2024 · Translational Psychiatry
  29. Automated Depression Detection from Tweets: a Comparison of NLP Techniques
    Emirhan Balcı, Esra Saraç Eşsiz · 2024 · International Artificial Intelligence and Data Processing Symposium (IDAP)
  30. Lost in descent: Complications of cryptorchidism
    Lauren Facer, Theresa X. Pham, Douglas M. Rogers · 2022 · Radiology Case Reports
  31. The pharmacokinetics of ketamine following intramuscular injection to F344 rats
    Benjamin C. Moeller, Brenna Espelien, Waylon Weber, Philip J. Kuehl, Melanie Doyle‐Eisele, C. Edwin Garner, Jacob D. McDonald, Efrain E. Garcia, Robert E. Raulli, Judith Laney · 2018 · Drug Testing and Analysis
  32. Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant
    Julia Zaccarelli‐Magalhães, André Rinaldi Fukushima, Natália Chermont dos Santos Moreira, Marianna Manes, Gabriel Abreu, Esther Lopes Ricci, Paula A. Faria Waziry, Helenice de Souza Spinosa · 2019 · Pharmacological Reports
  33. The immunomodulatory effect of ketamine in depression.
    Łukasz Piotr Szałach, Katarzyna Aleksandra Lisowska, Jakub Słupski, Adam Włodarczyk, Natalia Górska, Joanna Szarmach, Katarzyna Jakuszkowiak‐Wojten, Maria Gałuszko‐Węgielnik, Mariusz Stanisław Wiglusz, Alina Wilkowska et al. · 2019 · PubMed
  34. Simultaneous Application of Lidocaine and Ketamine During Ambulatory Infusion Therapy: A Retrospective Analysis
    Julia Striebel, Wilhelm Ruppen, Tobias Schneider · 2023 · Pain Management
  35. Effect of Acute Ketamine Treatment on Sympathetic Regulation Indexed by Electrodermal Activity in Adolescent Major Depression
    Veronika Kovacova, Andrea Macejova, Ingrid Tonhajzerová, Zuzana Višňovcová, Nikola Ferencová, Zuzana Mlyncekova, Tomas Kukucka, Ivan Farský, Slavomír Nosáľ, Igor Ondrejka · 2024 · Pharmaceuticals
  36. PACAP/VIP in the prefrontal cortex mediates the rapid antidepressant effects of zhizichi decoction
    Li Ren, Yue Fan, Huoqing Luo, Ji Hu, Jingqing Hu · 2024 · Journal of Ethnopharmacology
  37. Putative effects of cannabidiol in depression and synaptic plasticity
    Sâmia R.L. Joca, Gabriela Pandini Silote, Ariandra Guerini Sartim, Amanda J. Sales, Francisco Silveira Guimarães, Gregers Wegener · 2021 · Elsevier eBooks
  38. Clinical use of ketamine in psychiatric disorders
    Sina Dehestani, Amir Hooshang Mohammadpour, Seyed Alireza Sadjadi, Thozhukat Sathyapalan, Amirhossein Sahebkar · 2022 · Annales Médico-psychologiques revue psychiatrique
  39. Phosphoproteomics implicates glutamatergic and dopaminergic signalling in the antidepressant-like properties of the iron chelator deferiprone
    Volkan Uzungil, Sandra Luza, Carlos Opazo, Isaline Mees, Shanshan Li, Ching‐Seng Ang, Nicholas A. Williamson, Ashley Ian Bush, Anthony John Hannan, Thibault Renoir · 2024 · Neuropharmacology
  40. Gender Differences in Adverse Events of Ketamine Drugs: A Real‐World Study Based on FAERS
    Jun Zhang, Qin Guo, Ran Zhang, Menghui Wei, Zhongbiao Nie · 2024 · Journal of Clinical Pharmacy and Therapeutics
  41. Ketamine as a Rapid-Acting Antidepressant: Promising Clinical and Basic Research
    Andrew N. Tuck, Danish H. Ghazali · 2017 · American Journal of Psychiatry Residents Journal
  42. Modulation of functional network co-activation pattern dynamics following ketamine treatment in major depression
    Brandon Taraku, Jason S. Nomi, Artemis Zavaliangos‐Petropulu, Noor Al‐Sharif, Paloma Pfeiffer, Vera Norris, Shantanu H. Joshi, Randall T. Espinoza, Lucina Q. Uddin, Katherine L. Narr · 2025 · Imaging Neuroscience
  43. Ketamine enhances neurological function through neuronal and plasticity-related protein changes in rats with permanent middle cerebral artery occlusion
    Néstor I. Martínez-Torres, Jhonathan Cárdenas-Bedoya, Blanca Miriam Torres-Mendoza · 2025 · Metabolic Brain Disease
  44. An effect of 3-oxypyridine and succinic acid derivatives on the time of reduction of anxiety and depression symptoms in alcohol withdrawal treatment
    Илья Анатольевич Волчегорский, B.V. Izarovskii, Шамаева Татьяна Николаевна, I Izarovskaia · 2021 · S S Korsakov Journal of Neurology and Psychiatry
  45. Ketamine causes poor maternal care in rats with postpartum depression and leads to few behavioral and neurochemical alterations on male offspring
    Julia Zaccarelli‐Magalhães, Gabriel R. Abreu, André Rinaldi Fukushima, Lorena de Paula Pantaleon, Beatriz B. Ribeiro, Camila Munhoz, Marianna Manes, Mayara A. de Lima, Júlia Miglioli, Jorge Camilo Flório et al. · 2023 · Behavioural Brain Research
  46. Lamotrigine is not associated with differential clinical outcomes in a real-world sample of patients with unipolar depression receiving ketamine or esketamine
    Mia C Santucci, Rachel B. Katz, Brian P. Pittman, Sina Nikayin, Samuel T. Wilkinson · 2025 · Psychopharmacology
  47. Structure-Based Virtual Screening to Identify Negative Allosteric Modulators of NMDA
    Zaid Anis Sherwani, Ruqaiya Khalil, Mohammad Nur‐e‐Alam, Sarfaraz Ahmed, Zaheer Ul‐Haq · 2022 · Medicinal Chemistry
  48. A qualitative investigation of the Montgomery–Åsberg depression rating scale: discrepancies in rater perceptions and data trends in remote assessments of rapid-acting antidepressants in treatment resistant depression
    Gianna Capodilupo, Raymond Blattner, Anita Must, Silvia Gamazo Navarro, Mark G. A. Opler · 2024 · Frontiers in Psychiatry
  49. Recent advances in the synthesis of antidepressant derivatives: pharmacologic insights for mood disorders
    Jeetendra Kumar Gupta, Kuldeep Singh, Alok Bhatt, Prateek Porwal, Rekha Rani, Anubhav Dubey, Divya Jain, Sachchida Nand · 2024 · 3 Biotech
  50. Updates on Preclinical and Translational Neuroscience of Mood Disorders
    Nicholas Mischel, Michael D. Kritzer, Ashwin A. Patkar, Prakash S. Masand, Steven T. Szabo · 2019 · Journal of Clinical Psychopharmacology
  51. Ketamine for Treatment-Resistant Depression: A Gateway to Novel Treatment Approaches
    Barbara J. Limandri · 2018 · Journal of Psychosocial Nursing and Mental Health Services
  52. Does Peritraumatic Ketamine Reduce Symptoms of Post-Traumatic Stress Disorder?
    Jack D. Brodeur, Ryley Mancine, Alyse Folino Ley, Jed G. Magen · 2020 · Spartan Medical Research Journal
  53. Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials
    Asim A. Shah, FNU Sawaira, Misbahuddin, Muneeb Shad Mohmand, Suleman Khan, Z A R Y A B Bacha, Hammad Iftikhar, Asad Jamal, Fazia Khattak, Aizaz Anwar Khalid et al. · 2026 · Brain and Behavior
  54. Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience
    Rebeca Cohen, João Bastos, Catarina Cunha, M. Marguilho, Ana Valle Sancho, Maria João Matos Silva, Franklin King, Pedro Castro-Rodrigues · 2026 · General Hospital Psychiatry
  55. Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression
    Aristide Merola, Yuki Mukai, Tjerk Bueters, Paulette Ceesay, Nicole Dupre, Christine I. Furtek, Gerard Sanacora, Michael E. Thase, Steven D. Targum, Sean M. Smith et al. · 2026 · Journal of Clinical Psychopharmacology
  56. Ketamin in der Schmerztherapie
    Rae Frances Bell, Eija Anneli Kalso · 2019 · Der Schmerz
  57. Hesperidin produces antidepressant effects by activating AMPA receptor: enhancing synaptic proteins to promote hippocampal neuronal activities
    Bo Pang, Ting Cao · 2024 · Behavioural Pharmacology
  58. Ketamine as a Rapid Antidepressant
    Cristina Cusin · 2018 · Springer eBooks
  59. Ionotropic glutamate receptors: Still exciting after all these years
    Graham L. Collingridge, David Lodge, Mark L. Mayer, Gina G. Turrigiano, Bruno G. Frenguelli · 2016 · Neuropharmacology
  60. Introduction: Nanomedicine in the Brain
    Tianqi Li, Liwen Huang, Xue Xue · 2019 · Springer eBooks
  61. The Efficacy of N-Acetyl-Cysteine (NAC) Supplementation in FST Model for Screening Antidepressants
    Adejoke Elizabeth Memudu · 2022 · Basic and Clinical Neuroscience Journal
  62. Is poor dose selection undermining the translational validity of antidepressant research involving animal models?
    Dasha Anderson, Justyna K. Hinchcliffe, Megan G. Jackson, Emma S. J. Robinson · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  63. From synapse to strategy: a bibliometric map of ionotropic glutamate receptors in depression
    Yunsheng Liu, Rongde Zhong, Fenyong Yao, Huafu Zhao, Yuyan Wang, Changjian Li, Jinfang Zhang, Zengwei Kou · 2026 · Naunyn-Schmiedeberg s Archives of Pharmacology
  64. Farmakoterapia depresji u pacjentów z zaawansowanymi chorobami
    Jakub Grabowski, Mateusz Przybylak · 2019 · Palliative Medicine in Practice
  65. Les propriétés antidépressives de la kétamine
    Charles Y. Desfossés, Pierre Blier · 2021 · médecine/sciences
  66. Um novo olhar para o tratamento do transtorno depressivo maior: uma revisão dos estudos clínicos realizados com cetamina e escetamina
    Layza Kowalski, Eslen Delanogare, Tiago Bittencourt de Oliveira · 2021 · VITTALLE - Revista de Ciências da Saúde
  67. Management of Ketamine Extravasation in a Pediatric Patient During Procedural Sedation
    Samantha A Smith, Casey T. Fitzpatrick, Courtney L. Olesky, Ashley B Litchfield · 2022 · The Journal of Pediatric Pharmacology and Therapeutics
  68. Utilidad de medicamentos intranasales en urgencias
    Ricardo Bañuelos-Huerta, Ana Muñoz-Solís, Enrique Monares Zepeda, Janet Pérez-Morales · 2023 · Revista Chilena de Anestesia
  69. Exploring Ketamine's Repurposing for Treating Cocaine Use Disorder: A Ghanaian Perspective on Ethical and Legal Constraints
    Prince Opuni Frimpong · 2023 · Journal of Health, Medicine and Nursing
  70. Ketamin und Esketamin
    Cornelius Schüle, Gabi Koller, Uwe Herwig · 2024 · Nervenheilkunde
  71. Neurophysiologic Advance in Depressive Disorder
    Lin Xu, Rongrong Mao · 2019 · Advances in experimental medicine and biology
  72. Depression and Other Forms of Mental Illness
    William J. Freed · 2022 · Springer eBooks
  73. Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
    Tanaka, Masaru · 2026 · Biomedicines
  74. Novel approaches to measure physiological and behavioral responses to stress
    Jan Seidel · 2020
  75. Differential Effects of Repeated Low-Dose Ketamine on Cross-Frequency Interactions in Naïve and Preclinical Models of Movement Disorders
    Tony Ye · 2018 · UA Campus Repository (The University of Arizona)
  76. Chronic Stress Induces Specific Cellular and Morphological Astroglial Changes Associated with Depressive-like Phenotypes
    Dipashree Chatterjee · 2019 · TSpace (University of Toronto)
  77. Estudos comportamentais e neurofisiológicos da exposição prolongada à cetamina como antidepressivo e o modelo de separação materna para indução de depressão pós-parto em ratos
    Julia Zaccarelli‐Magalhães · 2021
  78. ウエイトトレーニング時のウォーミングアップ(2)クイックリフト実施時の各種競技アスリートの実践例
    陽介 槇野, 進一郎 下嶽, 力也 砂川 · 2008
  79. Nomogram for predicting major depression and suicidal ideation in medical residents: A multi-center cross-sectional study
    E Shaolong, Yixiao Zhang, Tianshu Ying, Song Bai · 2022 · Research Square
  80. Perspective Chapter: Ketamine, Depression, and Gender Bias
    Tahani K. Alshammari, Sarah Alseraye, Nouf Mohamed Al-Rasheed, Anfal F. Bin Dayel, Asma S. Alonazi, Jawza F. Al Sabhan, Musaad A. Alshammari · 2022 · IntechOpen eBooks
  81. Current Treatments for Depression
    John Harrison Krystal, Dennis S. Charney · 2017 · Oxford University Press eBooks
  82. Faculty Opinions recommendation of Prefrontal connectivity and glutamate transmission: relevance to depression pathophysiology and ketamine treatment.
    Hanns Möhler · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  83. Unipolar Depression And Its Treatment
    Stephen M. Stahl · 2022 · Cambridge University Press eBooks
  84. Ketamine Causes Poor Maternal Care and Stereotype Behavior in Rats with Postpartum Depression and Anxiety-Like Behavior and Neurochemical Alterations on the Offspring
    Julia Zaccarelli‐Magalhães, Gabriel R. Abreu, André Rinaldi Fukushima, Lorena de Paula Pantaleon, Beatriz B. Ribeiro, Camila Munhoz, Mariana Manes, Mayara A. de Lima, Júlia Miglioli, Jorge Camilo Flório et al. · 2023 · SSRN Electronic Journal
  85. New Frontiers in Ketamine Research: From Mechanisms of Action to Novel Psychiatric Treatment Approaches
    Marcus Christian Rosenhagen, Julien Elowe, Alberto Maria Forte, Nicolas Schaad · 2023 · American Journal of Psychiatry and Neuroscience
  86. Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
    Sunita D. Singh · 2024 · Cambridge University Press eBooks
  87. Plasma leptin levels are lower in females, but not males, with ketamine use disorder
    Ming‐Chyi Huang, Li-Jung Chiang, Wan-Hsi Chien, Tung‐Hsia Liu, Chun-Hsin Chen, Yu‐Li Liu · 2024 · The American Journal of Drug and Alcohol Abuse
  88. Current Treatments for Depression
    Maurizio Fava M. D, John Harrison Krystal · 2025 · Oxford University Press eBooks
  89. The Lysing of Catatonia With Intravenous Ketamine Prior to Definitive Treatment With Electroconvulsive Therapy
    Erich J. Conrad, Zachary F. Stielper, Isabelle V. Mermilliod, Matthew R. Eng · 2025 · Journal of Ect
  90. Hepatobiliary Complications Associated With Ketamine Use: Clinical Insights and Future Directions
    Hafiza Wajeeha Waheed, Muhammad R Ashraf, Talha Sajjad, Hanzala Jehangir, Iqra Baig, Ahmad Zulaid, Abdul Rehman Nasir, Allah Dad · 2025 · Cureus
  91. Oral Ketamine as a Treatment for Hyper‐Responsiveness and Anxiety in a Female Allen's Swamp Monkey (Allenopithecus nigroviridis)
    Juliette Nye, Elena Hoellein Less, Patricia M. Dennis · 2025 · Veterinary Medicine and Science
  92. Treatment-resistant bipolar depression
    Alexandre Paim Díaz, Brisa Simões Fernandes, João Quevedo, Marsal Sanches, Jair C. Soares · 2022 · Elsevier eBooks
  93. Esketamine for Treatment-Resistant Depression: A Case Series and Literature Review
    Muhammad Abbas, David B. Adams, Jack Noto, Renzmark D Vallesteros, Talitha West · 2025 · Cureus
  94. Ketamine and crocin exposure modulate anxiety, depression, memory, and pain processes in adolescent female Wistar rats
    Sakineh Alijanpour, Seyed Parsa Golshani, Mohaddeseh Ebrahimi-Ghiri, Mohammad‐Reza Zarrindast, Fatemeh Khakpai · 2025 · Behavioural Pharmacology
  95. Time-dependent biphasic alterations in brain metabolism following chronic ketamine exposure in mice
    Seo-Hyun Lim, Young‐Suk Choi, Eosu Kim, Chul Hoon Kim, Ho‐Taek Song · 2025 · Frontiers in Pharmacology
  96. Ketamine’s impact on rumination-related brain dynamics: insights from a randomized controlled fMRI trial
    Marvin Sören Meiering, David Weigner, Matti Gärtner, Luisa Carstens, Christian Keicher, Gerd Luippold, Andreas Wunder, Anne Weigand, Simone Grimm · 2026 · Translational Psychiatry
  97. Progress on the neurotrophic effects of antidepressant drugs
    Pan Jing, Xi-Cheng Liu, Xiao-Peng Yin, Ye Fu, Qing Tian, Xiao-Bin Zhang · 2026 · World Journal of Psychiatry
  98. Anethole probably through modulation of neuroinflammation and CA3 changes in the hippocampus exerts antidepressant-like effect in maternally separated male mice
    Ramina Khodadadian, Mohammad Shadkhast, Shima Balali-Dehkordi, Hossein Amini-Khoei · 2026 · PharmaNutrition
  99. Prise en charge médicamenteuse des patients souffrant de douleur chronique réfractaire
    Alexandrine Corriger · 2019 · theses.fr (ABES)
  100. Ketamin-assistierte Psychotherapie in der Suchtmedizin: ein narratives Review unter Berücksichtigung von Einzel- und Gruppentherapieansätzen
    Sophie Schiefler, Jonas P. Montagna · 2026 · Suchttherapie